Article Text

Download PDFPDF
Randomized Phase 3 Trial Comparing 2 Cisplatin Dose Schedules in 326 Patients With Locally Advanced Squamous Cell Cervical Carcinoma: Long-Term Follow-Up
  1. Viorica Magdalena Nagy, PhD, MD*,,
  2. Claudia Ordeanu, PhD, MD*,
  3. Ovidiu Coza, PhD, MD*,,
  4. Cristian Rancea Alin, PhD, MD*,,
  5. Alexandru Traila, PhD, MD* and
  6. Nicolae Todor, PhD*
  1. *Oncology Institute“Prof. Dr. Ion Chiricuţâ”, Cluj-Napoca, Romania, and
  2. University of Medicine and Pharmacy“Iuliu Haţieganu”, Cluj-Napoca, Romania.
  1. Address correspondence and reprint requests to Nicolae Todor, PhD, Oncology Institute “Prof. Dr. Ion Chiricuţâ”, Cluj-Napoca, Romania. E-mail:


Objective The evaluation of 5-year results obtained through 2 radiochemotherapy (RCT) regimens: cisplatin (CDDP), 20 mg/m2 × 5 days every 21 days; and CDDP, 40 mg/m2 per week in locally advanced cervical carcinoma.

Methods/Materials In this single-institution prospective randomized phase 3 study, 326 patients with stage IIB to IIIB squamous cell cervical carcinoma treated from March 2003 to March 2005 were included. One hundred sixty patients (49%) had stage IIB cervical carcinoma, 103 patients (31.5%) had stage IIIA cervical carcinoma, and 63 patients (19.5%) had stage IIIB cervical carcinoma. The patients were randomly assigned to 2 therapeutic arms: 164 patients in arm A (5 days) concurrent RCT with CDDP, 20 mg/m2 per day, days 1 to 5 every 21 days; and 162 patients in arm B (weekly), concurrent RCT with CDDP, 40 mg/m2 per day weekly. All patients were treated with external beam radiotherapy on the abdominopelvic region using 15-MV x-rays and a cervical boost using the x-rays arch technique or medium-dose-rate intracavitary brachytherapy.

Results The 5-year survival rate obtained through the 2 RCT regimens are not statistically different, even if a tendency of superiority can be observed in the 5-day arm as far as overall survival (78% in arm A vs 72% in arm B; p = 0.14) and disease-free survival (73% in arm A and 69% in arm B; p = 0.09) are concerned. Five-year local relapse-free survival was significantly superior in the 5-day CDDP arm (87%) in comparison with the weekly CDDP arm (77%); p < 0.01. In the 5-day arm, local relapse rate was twice lower, 21/164 (13%), compared with the weekly arm, 40/162 (25%); p < 0.01). Distance failures were identical in the 2 therapeutic groups: 22/164 (13%) and 21/162 (13%), respectively, which shows the superiority of arm A regarding local control.

Conclusions The results of our study demonstrate that RCT with cisplatin, 20 mg/m2 × 5 days every 21 days, is superior regarding local efficacy and is less toxic compared with the weekly chemotherapy regimen.

  • Cervical cancer
  • Concomitant radio-chemotherapy
  • Cisplatin

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.